µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y521 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä®½·Ã¤³ÎÂ÷´ÜÁ¦ Calcium-channel blockers causing adverse effects in therapeutic use
Y522 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç׺ÎÁ¤¸ÆÁ¦ Other antidysrhythmic drugs, NEC causing adverse effects in therapeutic use
Y523 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº °ü»óµ¿¸ÆÈ®ÀåÁ¦ Coronary vasodilators, NEC causing adverse effects in therapeutic use
Y523 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â µðÇǸ®´Ù¸ô Dipyridamole causing adverse effects in therapeutic use
Y524 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò¾ïÁ¦Á¦ Angiotensin-converting-enzyme inhibitors causing adverse effects in therapeutic use
Y525 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç×°íÇ÷¾ÐÁ¦ Other antihypertensive drugs, NEC causing adverse effects in therapeutic use
Y525 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å©·Î´Ïµò Clonidine causing adverse effects in therapeutic use
Y525 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸¾Æ³×Ƽµò Guanethidine causing adverse effects in therapeutic use
Y525 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¶ó¿ì¿ùÇÇ¾Æ Rauwolfia causing adverse effects in therapeutic use
Y526 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°íÁöÁúÇ÷Áõ ¹× Ç×µ¿¸Æ°æÈ­Áõ ¾à¹° Antihyperlipidemic and antiarteriosclerotic drugs causing adverse effects in therapeutic use
Y527 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸»ÃÊÇ÷°üÈ®ÀåÁ¦ Peripheral vasodilators causing adverse effects in therapeutic use
Y527 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´ÏÄÚÆ¾»êÀ¯µµÃ¼ Nicotinic acid derivatives causing adverse effects in therapeutic use
Y528 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Á¤¸Æ·ùÁ¦, °æÈ­Á¦ Æ÷ÇÔ Antivaricose drugs, including sclerosing agents causing adverse effects in therapeutic use
Y529 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ÉÇ÷°ü°èÅë¿¡ ÀÏÂ÷ÀûÀ¸·Î ¿µÇâÀ» ÁÖ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ¾à¹° Other and unspecified agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use
Y53 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use
Y530 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È÷½ºÅ¸¹Î H2-¼ö¿ëü±æÇ×Á¦ Histamine H2-receptor antagonists causing adverse effects in therapeutic use
Y531 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×»êÁ¦ ¹× Ç×À§»êºÐºñÁ¦ Other antacids and anti-gastric-secretion agents causing adverse effects in therapeutic use
Y532 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÈïºÐ¼º ¼³»çÁ¦ Stimulant laxative causing adverse effects in therapeutic use
Y533 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½Ä¿°¼ö¿Í »ïÅõÄ¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼º ¼³»çÁ¦ Saline and osmotic laxatives causing adverse effects in therapeutic use
Y534 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¼³»çÁ¦ Other laxatives causing adverse effects in therapeutic use
1911  1912  1913  1914  [1915] 1916  1917  1918  1919  1920